Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$1.16
-AU$0.14(-11.97%)
At close: 4:00 PM EDT
AU$1.16
-AU$0.14(-11.97%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume503.64K
Average Volume (3M)175.32K
Market Cap
AU$28.11M
Enterprise ValueAU$12.61
Total Cash (Recent Filing)AU$6.48M
Total Debt (Recent Filing)AU$14.78K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding30,890,978
10 Day Avg. Volume66,258
30 Day Avg. Volume175,323
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.22
Price to Sales (P/S)9.54
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRevenue is expanding at a meaningful rate, indicating increasing commercial activity and potential product adoption. Although the base remains small, sustained growth could improve operating leverage over time if OncoSil converts its focused oncology offering into broader recurring demand.
Low Leverage Balance SheetMinimal debt reduces interest burden and refinancing exposure, giving the company greater flexibility while it develops and commercializes its therapy. This balance-sheet strength can help preserve strategic options during a period when operating profitability and cash generation remain under pressure.
Specialized Oncology Device PlatformThe company is focused on a specific interventional-oncology application rather than a broad, undifferentiated medical-device portfolio. A targeted therapy addressing pancreatic tumors could support specialized clinical positioning as evidence, regulatory approvals, and international commercialization progress.
Bears Say
Persistent UnprofitabilityNegative gross profit and large operating losses show that current revenue is not yet sufficient to cover the economics of the business. Continued losses may limit internal reinvestment and make future improvement dependent on materially higher sales, better margins, or lower operating costs.
Ongoing Cash BurnPersistent negative operating and free cash flow indicates that the company is consuming cash to support its operations rather than funding them internally. Without sustained improvement, cash burn can constrain product development and commercialization while increasing dependence on external financing.
Potential Dilution RiskIf losses and cash outflows continue, the company may need to raise additional capital to maintain operations and commercial initiatives. Equity financing could dilute existing holders and increase execution pressure, particularly before the business reaches break-even or generates dependable cash flow.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$28.11M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 174 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 28, 2026. The company reported -AU$0.236 earnings per share for the quarter.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,890,978 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.236 in its last earnings report. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 88%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―